Tag: heart failure
-
DOAC Outcomes in NVAF Linked to Echocardiographic Hemodynamics
Overview: DOACs, NVAF, and the role of cardiac hemodynamics Non-valvular atrial fibrillation (NVAF) requires careful stroke prevention, with direct oral anticoagulants (DOACs) such as apixaban, rivaroxaban, and dabigatran replacing warfarin in many patients. While DOACs have demonstrated non-inferiority to warfarin in large trials, real-world data reveal nuances in bleeding and stroke risk that may hinge…
-
Knowledge Domain and Emerging Trends on Dapagliflozin for Heart Failure: A Bibliometric Analysis (2012–2024)
Introduction Dapagliflozin, a leading SGLT2 inhibitor, has evolved from a glucose-lowering agent to a cornerstone therapy for heart failure (HF). Built on pivotal trials like DAPA-HF and DELIVER, dapagliflozin now targets a broad spectrum of HF patients, including those without diabetes. A recent bibliometric analysis of literature from 2012 to 2024 maps the global research…
-
Knowledge Domain and Emerging Trends on Dapagliflozin for Heart Failure: A Bibliometric View (2012–2024)
Introduction: Dapagliflozin as a Cornerstone in Heart Failure Therapy Heart failure (HF) remains a global healthcare challenge with rising prevalence and substantial economic burden. Dapagliflozin, an SGLT2 inhibitor, emerged as a pivotal therapy beyond glucose control, driven by landmark trials such as DAPA-HF. A bibliometric analysis of research from 2012 to 2024 reveals how scientific…
-
Knowledge Gaps and Emerging Trends in Dapagliflozin for Heart Failure: A 2012–2024 Bibliometric Analysis
Introduction Dapagliflozin, a pioneering SGLT2 inhibitor, has evolved from a diabetes medication to a cornerstone therapy for heart failure (HF). Built on pivotal trials such as DAPA-HF and DELIVER, its role now spans reduced and preserved ejection fraction HF subtypes, with ongoing investigations into cardiorenal protection and fibrosis modulation. This article interprets a comprehensive bibliometric…
-
Heart Failure in AML: New Evidence on Anthracycline Cardiotoxicity
Overview A comprehensive meta-analysis led by researchers from the Netherlands sheds new light on the risk of heart failure in patients with acute myeloid leukemia (AML) who receive anthracycline-based induction therapy. By systematically reviewing 41 studies including 5,995 AML patients, the study consolidates what clinicians have long suspected: anthracyclines, while effective for achieving remission, carry…
-
Heart Failure in AML: New Evidence Emerges
New Evidence on Cardiotoxicity in AML Treatment A comprehensive new systematic review analyzed 41 studies involving 5,995 patients with acute myeloid leukemia (AML) who received anthracycline-based regimens during remission induction. The pooled rate of heart failure in this population was 3.2%, with notable differences depending on the anthracycline used: 2.3% with daunorubicin, 5.0% with idarubicin,…
-
New Evidence on Heart Failure in AML Treated with Anthracyclines: What Clinicians Need to Know
Overview Heart failure in AML remains a critical concern for patients undergoing induction therapy with anthracycline-based regimens. A comprehensive meta-analysis led by researchers in the Netherlands analyzed 41 studies totaling 5,995 AML patients. The study quantified the burden of heart failure and highlighted substantial variability depending on the specific anthracycline used. These findings reinforce the…
-
Cardiology Wait Times: Living with Heart Failure in Limbo
Patients wait for cardiology care amid growing concerns For people with heart conditions, timely access to cardiology specialists isn’t a luxury—it’s a matter of health and peace of mind. The case of 58-year-old Scott McKenna, who learned seven years after first experiencing chest pain that he has heart failure, highlights the emotional and physical toll…
-
Cardiology Waiting Times Raise Fear of Heart Attack
Overview: Waiting for Cardiology Care Takes a Toll For many patients with heart concerns, delays in seeing a cardiologist mean more than just longer to-do lists and medical forms — they carry real, frightening consequences for wellbeing. In Scarborough, 58-year-old Scott McKenna describes his seven-year journey to a heart failure diagnosis as a period of…
-
New Horizons in Heart Failure Treatment: Clinician Education
Introduction: A new ACC program to elevate heart failure care The American College of Cardiology (ACC) is launching Transformation of HF Care: New Horizons in Treatment, an 18-month education program designed to equip clinicians with the latest advances in heart failure (HF) management. The initiative seeks to bridge gaps between evolving research and everyday practice,…